How were (MDVN)'s earnings last quarter?

(MDVN) (NASDAQ:MDVN) announced its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to analysts' expectations of $214.52 million. The firm's quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.58 EPS.

What other stocks do shareholders of (MDVN) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (MDVN) investors own include Puma Biotechnology (PBYI) , BioMarin Pharmaceutical (BMRN) , Incyte (INCY) , First Solar (FSLR) , United Airlines (UAL) , Dynavax Technologies (DVAX) , (KITE) (KITE) , Array Technologies (ARRY) , Freeport-McMoRan (FCX) and

NASDAQ:MDVN

(MDVN) (MDVN) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free MDVN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $81.44
▼
$81.44
50-Day Range: N/A
52-Week Range: $26.41
▼
$81.48

Volume: N/A
Average Volume: 3.55 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get (MDVN) alerts:

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About (MDVN) Stock (NASDAQ:MDVN)

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

MDVN Stock News Headlines

March 27, 2024 | nasdaq.com

Notable ETF Outflow Detected - HYLB

January 28, 2024 | msn.com

Nearly a thousand take chilly plunge off Oak Street Beach for annual fundraiser

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

January 8, 2024 | msn.com

Packers beat Bears 17-9 to clinch playoff spot, head to Dallas

December 30, 2023 | msn.com

Google agrees to settle $5-B lawsuit over ‘incognito’ mode

December 29, 2023 | msn.com

Kanye West and Wife Bianca Censori Will Have a 'Fiery' Start to 2024, Psychic Predicts

September 2, 2023 | thestreet.com

Medivation Alzheimer's Drug Fails Pivotal Study

June 26, 2023 | thestreet.com

Medivation (MDVN) Stock Falling After Earnings Estimates Cut

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

June 26, 2023 | thestreet.com

Medivation (MDVN) Stock Falling After Earnings Estimates Cut

June 13, 2023 | morningstar.com

Core Medalist ETFs

May 31, 2023 | bbc.co.uk

The Connor Phillips Show

April 21, 2023 | thestreet.com

Incyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation Deal

April 21, 2023 | thestreet.com

Medivation Stock Hits New 52-Week High (MDVN)

April 1, 2023 | msn.com

Mavs Lose to Heat, Play-In Hopes Continue to Take Major Hits

March 8, 2023 | msn.com

Millie Bobby Brown is 'ready to leave Stranger Things

January 26, 2023 | msn.com

Lake Nacogdoches notches its first 2023 Legacy ShareLunker

January 15, 2023 | msn.com

Ex-Huddersfield Town boss Danny Cowley pens emotional goodbye message to Portsmouth supporters

December 29, 2022 | msn.com

Goody’s Name Creates Another Addams Family Wednesday Mystery

December 25, 2022 | thestreet.com

Medivation (MDVN) Stock Surges, Will Explore Sale

October 18, 2022 | finance.yahoo.com

Jupiter Wellness’s Potential New OTC Drug Could Put Some More Joy Back Into Breast Cancer Survivors’ Lives - Yahoo Finance

October 10, 2022 | msn.com

NBC played the 'That’s So Raven' theme and people are freaking out about it: Best memes & tweets

October 7, 2022 | marketscreener.com

Portage Biotech : NOTICE OF ANNUAL GENERAL MEETING - Form 6-K - Marketscreener.com

August 5, 2022 | msn.com

The Impressions star Sam Gooden dies aged 87

July 16, 2022 | thestreet.com

Cramer's Top Stock Picks: BMY NDLS NFLX MDVN SGEN BMRN

May 31, 2022 | thestreet.com

The 5 Dumbest Things on Wall Street This Week: Aug. 3

March 24, 2022 | benzinga.com

Option Alert: MDVN 4,950 Jul $65 Call @Bid @$0.30 - Benzinga - Benzinga

See More Headlines

Receive MDVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/09/2016
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:MDVN
CUSIP: 58501N10
CIK: 1011835
Web: www.medivation.com
Phone: +1-415-5433470
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

MDVN Stock Analysis - Frequently Asked Questions

How were (MDVN)'s earnings last quarter?: (MDVN) (NASDAQ:MDVN) announced its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to analysts' expectations of $214.52 million. The firm's quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.58 EPS.
What other stocks do shareholders of (MDVN) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

This page (NASDAQ:MDVN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

(MDVN) (MDVN) Stock Price, News & Analysis

About (MDVN) Stock (NASDAQ:MDVN)

MDVN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

MDVN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info